Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Peglispro vs Glargine on Insulin Sensitivity in T2DM
NCT02197520Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Average Glucose Infusion Rate at Day 33. Started Jul 2014; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02197520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197520.